Background: The local anaesthetic prilocaine has a low systemic toxicity mainly because of a high absorption in the lung and a large volume of distribution and thus is associated with a lower risk of neurological or cardiac side-effects. However, the major disadvantage is the formation of methaemoglobin by its metabolite o-toluidine. This prospective observational study was performed to identify factors that are associated with increased prilocaine-induced methaemoglobinaemia. Patients and methods: One Hundred and sixty two patients undergoing major knee surgery under general anaesthesia combined with peripheral nerve blocks (femoral nerve block, combined femoral/sciatic nerve block or lumbar plexus block) received a single bolus injection of 300 or 400 mg prilocaine about 30 min before surgery via a catheter. The proper placement was verified using nerve stimulation via a stimulating catheter. Three hours after prilocaine injection, venous blood samples were drawn and methaemoglobin levels were measured by standard photometric technique. Data was subjected to a stepwise multiple regression analysis. Results: The mean methaemoglobin for all patients was 2.7% (range: 0.9-15.4%). A higher dose of prilocaine and younger age were the most important predictive factors for higher methaemoglobin formation. Female sex and to a lesser extent the use of high-concentration/low-volume prilocaine also increased methaemoglobin levels. These four factors of the model explain 36% of the total variance. Other investigated factors, including the patient's height, weight, body mass index, the site of catheter insertion, the anaesthetist's judgement concerning the difficulty of catheter placement, duration of catheter placement or an inadvertent puncture of a venous or arterial vessel, had no significant impact on the concentration of methaemoglobin. Conclusion: The use of prilocaine for regional block is safe, since the older patients who might be more susceptible to suffer from clinical symptoms of methaemoglobinaemia usually form less methaemoglobin. However, since prediction of high methaemoglobin levels is difficult, anaesthesiologists performing regional blocks in patients who might be jeopardized by a decreased oxygen transport capacity should avoid high doses of prilocaine.
Introduction
For surgical procedures of the lower limb, plexus blocks and peripheral nerve blocks constitute a widely established analgesic procedure. After placing the nerve catheter it is important to provide fast onset of the block to improve the workflow within the operating theatre. This aim can be reached by using a drug with fast onset. Prilocaine is a medium-longacting local anaesthetic with a fast onset of action that is comparable with lidocaine and mepivacaine but has a significantly lower systemic toxicity [1, 2] . This is mainly because of a large virtual volume of distribution and a high absorption of the drug in the lung that protects to a great extent against systemic toxic reactions even in case of accidental intravascular injection [3, 4] . Various toxicologic studies showed about 50% lower blood levels of the drug compared to other fast-onset and medium-long-acting local anaesthetic agents [5] [6] [7] . However, prilocaine bears the disadvantage of the formation of methaemoglobin (met-Hb) induced by its metabolites o-toluidine and nitrosotoluidine [6] [7] [8] [9] [10] .
Maximum levels of met-Hb are usually reached 2-4 h after prilocaine injection, and return to normal range again after 8-24 h in most cases [7, 11] . A positive correlation has been shown between the prilocaine dose used for a nerve block, and the time until the maximum met-Hb peak was reached [11, 12] . Following a single dose of 300-600 mg prilocaine, met-Hb concentrations in the range of 15% can be detected. This is normally considered harmless, but in certain circumstances, e.g. in anaemic patients or in patients with compromised cardiopulmonary function high levels of met-Hb can become clinically relevant [13] .
In almost all clinical and laboratory trials, an enormous variation of met-Hb formation has been described. However, little is known about the underlying causes for the high inter-individual variation of metheamoglobinaemia after the administration of prilocaine.
The purpose of this study was to identify factors that are associated with increased formation of met-Hb and to elucidate groups of patients that might have an increased risk.
Patients and methods
Patients scheduled for major knee surgery were recruited to this prospective observational study. Following approval of the local ethics review board and written informed consent, patients were randomized to receive a femoral nerve catheter, a lumbar plexus catheter (psoas compartment catheter) or a combination of femoral and sciatic nerve catheters. This randomization was primarily performed to study the analgesic efficacy, the onset time of sensory block and the functional recovery in two distinct studies. Patients younger than 18-yr old, patients with a haemoglobin level lower than 120 g L Ϫ1 , known contraindications for the use of prilocaine (allergies against the drug or other amide-based local anaesthetics, glucose-6-phosphate dehydrogenase deficiency) and those who had contraindications for a regional anaesthesia procedure (infection at the puncture site, bleeding disorders) were not included.
A total of 162 patients, ASA I-III, undergoing major knee surgery were investigated. For all patients a stimulating catheter was used (Arrow StimuCath continuous nerve block set ® with 17-G Tuohy needle of 9 or 15 cm length and a 19-G catheter, Arrow ® , Germany). The technique to identify the femoral or sciatic nerve or the lumbar plexus with the stimulating needle was standardized and performed according to institutional practice. The nerve stimulator current was initially set at 1 mA, with 2 Hz and 0.3 ms (Stimuplex HNS 11; Braun, Germany). After initial appropriate motor response was noted with the needle the current was progressively reduced to р0.3 mA. The catheter was then slowly advanced 5 cm beyond the needle tip under continuous electric stimulation. The four anaesthetists performing the nerve blocks were asked to judge the difficulty of catheter positioning on a 4-point Likert scale (very easy, rather easy, rather difficult or very difficult).
All patients received prilocaine to induce the block via the catheter: 74 patients received prilocaine 2% 20 mL solution (400 mg), 62 patients had prilocaine 1% 30 mL solution (300 mg) and 26 had prilocaine 1% 40 mL solution (400 mg) (see Table 1 for details). Thereafter and during 48 h all patients received a continuous infusion of ropivacaine 0.2% via the nerve catheter.
About 30 min after initiating the block, general anaesthesia was induced with propofol, fentanyl, and rocuronium and maintained with desflurane in all patients.
Venous blood samples for measurement of met-Hb concentration were taken 180 min after completion of the local anaesthetic injection. The whole blood was immediately analysed for met-Hb using a Radiometer Copenhagen ABL520 blood gas analyser (Radiometer Copenhagen, Willich, Germany). Met-Hb was measured by photometric approach by light extinction method. For a blood sample with haemoglobin content between 102 and 151 g L Ϫ1 the same-day coefficient of variation for met-Hb measurements determined by repeated measures of a standardized probe was 0.2-0.3% and the between-day coefficient of variation was 0.3-0.4%.
The following data of potential influence on the formation of met-Hb were collected: gender, age, height, weight and body mass index (BMI), the technique of regional anaesthesia used, the given prilocaine dose and concentration, an inadvertent vascular puncture, bloody or liquid secretion at the catheter insertion site on the first day as surrogate measures of a higher degree of tissue injury and traumatic puncture, duration of catheter positioning, and difficulty of catheter positioning judged by the performing anaesthetist.
Statistics
These variables were subjected to a stepwise linear regression analysis using a backward technique. In each step the least significant factor was eliminated if P was greater than 0.05. The quality of the final regression model was judged using the amount of explained variance of the model and by checking if the standardized residuals were normally distributed using a normal quantile plot as a graphical tool and the Shapiro-Wilk test as a statistical confirmation. The Durbin-Watson statistic (a value between 0 and 4 with an optimum of 2.0), leverage plots [14] as a graphical tool, and the variance inflation factor (VIF) were used as indicators of autocorrelation or collinearity of parameters included in the model. Interactions between these factors were investigated using graphical tools (interaction profiles plots) offered by the statistical package used for data analysis (JMP 5.1; SAS Institute Inc., Cary, NC, USA).
A power analysis had revealed that 160 patients would provide a power of 99% to detect an increase of R 2 of 0.25 and higher, attributable to 10 or less independent variables using an F-test with a significance level of 0.01. Table 1 shows the patient characteristics data. The amount of formed met-Hb 3 h after block initialization with 300 mg or 400 mg prilocaine showed a remarkable inter-individual variation. The mean was 2.7% with values ranging from 0.9% up to 15.4%. Two female patients, aged 18 and 21 yr, respectively, both having received prilocaine 2% 20 mL solution through a femoral catheter, showed clinical signs of cyanosis, but with no further clinical symptoms or impact on subjective well-being. Met-Hb level in these two patients were 10.8% and 15.4%, respectively.
Results
Using a stepwise backward regression technique, we could identify four factors that were significant and independent predictors for increased formation of met-Hb. These factors are listed in Table 2 . Using the scaled beta-coefficients as an indicator for effect size, it becomes evident that prilocaine dose in mg kg Ϫ1 body weight (increasing met-Hb formation) and age (decreasing met-Hb formation) are the most important influencing factors. Gender (female sex was associated with increased met-Hb formation) and the concentration of the drug were less important factors. For the latter, a 2% prilocaine solution is associated with increased met-Hb formation compared to the same total dose of prilocaine in a 1% solution.
The variables that were removed from the model as insignificant are listed in Table 3 . They were sorted as to their step at which the factor was removed and thus this information can be used to judge the relative importance of a parameter even though it was not statistically significant on the 5% level.
The fit of the model was acceptable. About 36% of the variance of the data is explained by the four factors (P Ͻ 0.0001). The quality of the model was good with respect to some commonly used criteria. The residuals of the model (differences between the predicted and the actual levels of met-Hb) were distributed normally and there was no obvious evidence of autocorrelation or collinearity between the four factors included as significant in the final model (Durbin-Watson test: 1.99; no evidence of clustering using the leverage plots, and VIF for each of the four parameters between 1.04 and 1.19).
Discussion
Prilocaine is a medium-long-acting local anaesthetic with a fast onset of action, comparable with lidocaine and mepivacaine, but prilocaine has a far lower systemic toxicity on the cardiac and central nervous Continuous data are presented as median (25th-75th percentiles). Additionally, for the parameters that were included in the final regression model (italicized), the range is also presented in square brackets. For nominal data, the absolute and relative incidence, and for the parameter of the final regression model the type of coding (e.g. '0' or '1') is given.
system [1, 2] . Its large volume of distribution protects to a great extent against systemic toxic reactions even in case of accidental intravascular injection [3, 4] . Several toxicologic studies showed about 50% lower blood levels of the drug than the other fast-onset and medium-long-acting local anaesthetic agents [5] [6] [7] . However, prilocaine bears the disadvantage of the formation of met-Hb induced by its metabolites o-toluidine and nitrosotoluidine [6] [7] [8] [9] [10] .
The mechanism of met-Hb formation after prilocaine administration has been thoroughly investigated [5] [6] [7] [8] [9] [15] [16] [17] [18] [19] . In 1960, Löfgren and Tegner described the synthesis of this new local anaesthetic derived from lidocaine [19] . Sadove in 1965 was the first to report a sudden discolouration of the blood in the operation field after the use of prilocaine. Furthermore, he recognized a clear cyanosis in the otherwise healthy patient without any signs of acute cardiac or circulatory problems. The spectroscopic analysis demonstrated a distinct increase of met-Hb level [20] . The first spectroscopic examinations were followed by many extensive clinical and experimental studies during the next years.
In 1968, Nolte summarized the results of several investigations using prilocaine in doses of 200-2000 mg and in concentrations between 0.5% and 3% [11] . He concluded that there was good evidence for a dose-response relationship in the development of methaemoglobinaemia, with noticeable cyanosis occurring with administration of у600 mg. In a volunteer study, this author tested different doses of prilocaine in 30 healthy young men and women. A clear dose-response relationship was again detected, but a huge inter-individual variability was observed. In this study, even small doses of prilocaine (2 mg kg Ϫ1 ) led to a small but significant elevation of met-Hb that was more marked after 3-6 mg kg Ϫ1 [11] . Kortgen confirmed this doseresponsiveness again in 2003 [9] .
However, there is limited information about the underlying causes for the enormous inter-individual variability of methaemoglobinaemia levels observed after administration of comparable doses of prilocaine for regional anaesthesia.
This high and unpredictable variation of met-Hb formation may be a major reason why clinicians are reluctant to use prilocaine in daily practice even though it is licensed in their country 1 . Eifert, e.g. noticed a vide variation in met-Hb formation among his patients. Receiving a 700 mg prilocaine bolus injection for axillary plexus blockade, the median met-Hb level was 10.1%, with a maximum between 16% and 17%, but no patient showed clinical signs The step at which the factors were removed during the backward procedure and the P-value at which they were excluded are also listed.
*
Please note that P-values must not necessarily decrease in the order the factors are removed from the model, because the regression model is recalculated at each step. Table 2 . Parameters with a significant and independent influence on the met-Hb level following prilocaine injection for regional anaesthesia (results from the backward stepwise regression analysis). The beta-coefficients can be used to calculate the predicted met-Hb level for each patient. The scaled beta values are the estimates that would be obtained if all variables were scaled to zero mean and a range of Ϫ1 to 1 prior to performing the regression computations. Thus they are not affected by the scale of the variable (e.g. remains constant if age would be used in years instead of decades) and can be more easily compared with respect of effect size. CI: confidence interval.
of toxicity [6] . Nolte observed cyanosis after subcutaneous and intramuscular administration of 600 mg at the thigh in volunteers [11] , whereas other authors (Wagner, Kaiser and Tryba) reported about asymptomatic and acyanotic met-Hb elevations in their patients with the same amount of prilocaine [5, 7, 16] .
In our own study, we also identified the dose per kg body weight to be the strongest predictive factor for higher met-Hb levels. Since this variable includes the information of the absolute dose (300 or 400 mg) and weight, both parameters were removed early as insignificant from the model. This, of course, does not mean that they are not important parameters but the predictive power of both single parameters was transferred to the combined variable 'dose per kg body weight'. For each mg kg Ϫ1 , met-Hb was raised by more than 0.5%.
Such a dose-dependency has been described in numerous investigations (review in Refs [9, 11] ).
Another important factor was age. Per decade, the predicted level of met-Hb was reduced by an amount of about 0.3%. This, however, applies only for adult patients and cannot be extrapolated to children or even babies who are much more susceptible to met-Hb formation, since babies have easily oxidizable haemoglobin F and a haemoglobin-reductase enzyme with a lower activity [21] . This age dependency has not been described so far.
Our explanation for this observation is the reduced perfusion of tissues in older patients, and thus a slower prilocaine absorption. This is in accordance with the well-known clinical observation that the duration of block is highly dependent on age.
Female sex was also detected as an independent factor associated with the formation of higher levels of met-Hb. Overall, male patients had a 0.4% lower met-Hb value than female patients. This result is contradictory to the findings of Nolte [11] and Kortgen [9] , who could not demonstrate a significant sex-dependency on met-Hb formation. However, the impact of gender is mainly due to the lower haemoglobin concentrations of females compared to men rather than a true gender dependent effect.
Furthermore, using a higher concentration of prilocaine (2% vs. 1%) was found to be another risk factor independently from the absolute dose of the drug administered. The same patient developed a 0.36% higher met-Hb level if they received a 2% prilocaine solution instead of a 1% prilocaine solution, even if the total amount of prilocaine in mg was the same. The underlying mechanism remains unclear and has not yet been described so far.
It was interesting to note that both patients with met-Hb levels above 10% (10.8% and 15.4%) had the four risk factors present. Both were females, aged 18 and 21 yr, 54 and 64 kg of weight (7.4 and 6.3 mg kg Ϫ1 ) respectively, receiving prilocaine 2% 20 mL solution through a femoral catheter. Both developed cyanosis, but with no further clinical symptoms. These examples highlight the fact that even though respecting the recommended maximum bolus dose of 400 mg prilocaine without epinephrine-additive for infiltration anaesthesia, considerable levels of methaemoglobinaemia with clinical signs of cyanosis can occur.
The clinical consequences of methaemoglobinaemia are related to the blood level of met-Hb. Methaemoglobinaemia refers to the presence of greater than the normal physiological concentration of 1-2% metHb in erythrocytes [22] . Due to its dark blue colour, clinical cyanosis becomes apparent at a concentration of about 15% [22] . Clinical signs of cyanosis accompanied by a lack of responsiveness to 100% oxygen are highly suspicious of the presence of methaemoglobinaemia. According to Coleman, clinical symptoms like dyspnoea, nausea and tachycardia in otherwise healthy patients only occur at met-Hb levels exceeding 30%, deteriorating consciousness occurs at methaemoglobinaemia of around 55%, while levels of 70% are usually fatal [23] . According to some authors a met-Hb level of Ͻ30% should not be treated in patients without cardiopulmonary disease [23, 24] .
On the other hand, Bellamy [25] and Knobeloch [26] reported symptoms such as cyanosis, tachycardia and vertigo caused by a considerable lower met-Hb concentration in the range of 10%, a concentration that occurs quite often with prilocaine doses used for loco-regional anaesthesia.
According to Kreutz, induced toxic met-Hb levels are rare but can be life threatening [27] . We have to take into account that in patients with a severe cardiopulmonary disease or pronounced anaemia even met-Hb values far below the so-called toxic levels may lead to pathophysiological significance [13, 28] . Furthermore, patients with a propensity to develop met-Hb can develop much higher met-Hb values accompanied by severe symptoms with the same doses of prilocaine. Among those are babies with their easily oxidizable haemoglobin F and patients with congenital enzyme deficiencies such as the glucose-6-phosphate dehydrogenase deficiency [11] . But despite these theoretical considerations, Wald-Oboussier reported safe prilocaine administration (prilocaine 2% 6 mg kg Ϫ1 solution) in ten female patients with chronic renal failure requiring haemodialysis and a mean haemoglobin of 8.2%. Met-Hb levels were within the ranges measured in healthy patients [29] . Tryba confirmed this finding, as he did not encounter side-effects with 600 mg prilocaine in patients with renal insufficiency or chronic anaemia. Moreover, he stated that no complications were described so far in patients with glucose-6-phosphate dehydrogenase deficiency receiving prilocaine [7] .
In the light of the literature discussed and the obvious low clinical significance of met-Hb levels up to 30%, our data provide additional evidence for the safety profile of prilocaine, since the patients who are at an increased risk for high met-Hb levels (e.g. young women) are not likely to suffer clinical side-effects under these circumstances. However, the results from this study help to explain to a certain degree why there is such a high variability in the extent of methaemoglobinaemia between different individuals.
Despite these advances, the results presented demonstrate that an exact and reliable prediction of met-Hb formation is not possible. This highlights the need for a continuing careful use of prilocaine in patients who might be vulnerable to limited oxygen transport capacity, e.g. patient with pre-existing severe cardiopulmonary disease or pronounced anaemia.
